Key result
Low-molecular-weight heparin is replacing unfractionated heparin for initial VTE treatment due to its suitability for outpatient therapy and lower risk of complications like HIT and osteoporosis.
Why the study?
Does low-molecular-weight heparin improve safety and efficacy compared to unfractionated heparin in the initial treatment of venous thromboembolism?
Does low-molecular-weight heparin improve safety and efficacy compared to unfractionated heparin in the initial treatment of venous thromboembolism?
LMWH is the preferred initial anticoagulant for VTE due to its safety profile, predictable response, and suitability for outpatient therapy.
No takes yet. Share an insight, caveat, or question.
LMWH may be preferred for initial VTE; leaves open need for updated RCTs in contemporary populations.
McRae et al. (2004) conducted a review in Venous Thromboembolism. Low-molecular-weight heparin (LMWH) vs. Unfractionated heparin (UFH) was evaluated. Low-molecular-weight heparin is replacing unfractionated heparin for initial VTE treatment due to its suitability for outpatient therapy and lower risk of complications like HIT and osteoporosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: